secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001746473-26-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud

Pliant Therapeutics announces retirement of three directors and repricing of underwater stock options
--------------------------------------------------------------------------------

- Directors David Pyott, Katharine Knobil, and Suzanne Bruhn will retire effective at the 2026 Annual Meeting; all departures are not due to any disagreements.
- Board approved repricing of employee stock options (including executive officers) to $1.33 per share, effective April 17, 2026.
- Repricing covers options granted on or before March 1, 2025 under the 2015, 2020, and 2022 equity plans; eligible participants must stay through a 12-18 month retention period.
- Affected executive officers include CEO Bernard Coulie, CFO Keith Cummings, CHRO Lily Cheung, COO Minnie Kuo, CTO Delphine Imbert, and SVP Tim Machajewski.
- Underwater options were repriced to retain talent without additional dilution or cash compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000050/0001746473-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647326000050/plrx-20260414.htm
  HTML page:      https://secwatch.observer/filing/0001746473-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer